Business Context and Reporting Period
On October 28, 2022, LMF Acquisition Opportunities, Inc. ("LMAO") consummated a business combination with SeaStar Medical, Inc. ("SeaStar Medical"). Following the merger, LMAO was renamed SeaStar Medical Holding Corporation (the "Company"). The Company ceased to be a shell company and its common stock and warrants began trading on the Nasdaq Capital Market under the symbols "ICU" and "ICUCW," respectively, on October 31, 2022.
Key Financial Metrics and Capital Structure
This filing details the capitalization and debt structure resulting from the merger rather than operating performance metrics like revenue or profit, which are not provided in this specific 8-K text.
- Merger Consideration: Total consideration paid to SeaStar Medical stockholders was $85,408,328, consisting of 7,837,628 shares of Common Stock valued at $10.00 per share.
- Redemptions: Approximately 8,878,960 shares of LMAO Common Stock were redeemed by shareholders prior to closing.
- PIPE Financing: The Company raised $7.0 million through the issuance of 700,000 shares of Class A common stock at $10.00 per share to three institutional investors.
- Outstanding Shares: Immediately following the closing, there were 12,699,668 shares of Common Stock outstanding.
- Debt Obligations:
- LMFA Note: Amended credit agreement with LM Funding America, Inc. Interest rate reduced from 15% to 7% per annum; maturity extended to October 30, 2023.
- Sponsor Note: Consolidated promissory note with LMFAO Sponsor, LLC for an aggregate principal of $2,785,000. Interest rate is 7% per annum; maturity extended to October 30, 2023.
- Maxim Note: Promissory note with Maxim Group LLC for $4,182,353 (representing professional fees). Interest rate is 7% per annum; maturity extended to October 30, 2023.
Material Changes and Transactions
The primary material change is the completion of the SPAC merger, resulting in a new corporate entity and capital structure.
- Corporate Name Change: LMAO renamed to SeaStar Medical Holding Corporation.
- Debt Restructuring: Existing debt instruments were amended to extend maturities to October 30, 2023, and reduce interest rates to 7% per annum. All notes include a provision requiring the Company to use 5.0% of gross cash proceeds from future financing (after the first $500,000) to prepay the debt.
- Security Interests: The Company and SeaStar Medical granted security interests in substantially all assets to LMFA and the Sponsor to secure their respective notes. The Maxim Note remains unsecured.
- Equity Conversions: SeaStar Medical's convertible notes, preferred stock, warrants, options, and RSUs were automatically converted or assumed by the Company.
Guidance, Risks, and Management Commentary
The filing contains forward-looking statements regarding the anticipated benefits of the combination but does not provide specific financial guidance or revenue forecasts in this document.
- Management Changes: Ms. Caryl Baron was appointed as interim Chief Financial Officer effective October 28, 2022.
- Key Risks:
- Future capital requirements and ability to raise capital.
- Delays or challenges in obtaining FDA approval for SCD product candidates.
- Reliance on third-party suppliers and manufacturers.
- Product liability and regulatory lawsuits.
- Intellectual property protection.
- Disruption of operations due to the business combination.
- Dividends: The Company does not anticipate declaring or paying cash dividends for the foreseeable future, intending to retain earnings for business development.
Investor Verification Checklist
- Verify the pro forma financial information (Exhibit 99.2) to understand the combined entity's liquidity and debt load post-merger.
- Review the Intercreditor Agreement to understand the repayment hierarchy between LMFA, the Sponsor, and Maxim in the event of default.
- Confirm the status of FDA approvals for SeaStar Medical's product candidates, as this is a primary operational risk.
- Monitor the 5% prepayment covenant on debt instruments, which could impact future fundraising flexibility.
- Check the beneficial ownership table noting that LMFAO Sponsor, LLC holds approximately 45.1% of voting power (including warrants).